A 1-Year Open-Label Safety Extension Study of Pregabalin (CI-1008) in Patients With Anxiety Disorders Main objective : • To evaluate under open-label conditions the long-term safety and tolerability of pregabalin in doses ranging from 150 to 600 mg/day.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-00915275 AFTER ORAL ADMINISTRATION TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS FOR 4-WEEKS • To evaluate the effects of an oral dose of PF-00915275 (10 mg) on 24 hour mean daily glucose levels when administered as tablets for 4-weeks in subjects with T2DM.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Placebo-Controlled Study of Pregabalin in Elderly Patients With Generalized Anxiety Disorder 1. To evaluate the efficacy of pregabalin versus placebo in relieving the symptoms of Generalized Anxiety Disorder as measured by Hamilton Anxiety Rating Scale (HAM-A) 2. Evaluate the safety of pregab...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune